What question did this study set out to answer?

To determine whether adjuvant adriamycin chemotherapy reduces recurrence and metastatic spread in patients with primary osteosarcoma without detectable metastases following surgical amputation.

November 7, 1974New England Journal of Medicine

Amputation and Adriamycin in Primary Osteosarcoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does adjuvant adriamycin therapy delay metastases in patients with primary osteosarcoma post-amputation?

Population

21 patients with primary osteosarcoma without detectable metastases, post surgical amputation

Comparison

Adjuvant adriamycin therapy starting median two… vs Historical control

Design

Cohort

Follow-up

median >9 months

Authors

ECEngracio P. CortesMount Sinai Hospital JHJames F. HollandMayo Clinic JWJaw J. WangRoswell Park Comprehensive Cancer Center

Discussion

Member takes

Implication

May support adjuvant adriamycin post-osteosarcoma amputation; leaves open confirmation in randomized trials.

Key Points

To determine whether adjuvant adriamycin chemotherapy reduces recurrence and metastatic spread in patients with primary osteosarcoma without detectable metastases following surgical amputation.
Treated 21 osteosarcoma patients with adjuvant adriamycin (30 mg/m² daily for three consecutive days every four to six weeks for six courses) starting a median of two weeks post-amputation.
Tracked overall survival and pulmonary metastasis-free intervals over a follow-up of one to >32 months and compared outcomes to historical control data (n=145) using life-table analysis.
Nineteen of 21 patients survived after a median follow-up of >9 months, with five total relapses observed (two local and three pulmonary metastases).
Life-table analysis projected that 71% of treated patients remained free of pulmonary metastases at 18 months (95% CI, 43% to 100%), compared to 30% in historical surgical controls.

Structured PICO

Does adjuvant adriamycin therapy delay metastases in patients with primary osteosarcoma post-amputation?

Population

21 patients with primary osteosarcoma without detectable metastases, post surgical amputation

Intervention

Adjuvant adriamycin therapy (30 mg/m2 daily for three days, repeated every four to six weeks for six courses) starting median two weeks after amputation

Comparator

Historical control (series of 145 patients analyzed by Marcove et al.)

Outcome

Freedom from pulmonary metastases at 18 monthshard clinical

Adjuvant adriamycin therapy following amputation for primary osteosarcoma delays the onset of pulmonary metastases compared to historical controls.

Cite This Study

Cortes et al. (1974) studied this question.

synapsesocial.com/papers/6a7377753800ec2ea6a729f7 https://doi.org/10.1056/nejm197411072911903

View Full Paper

Ask AI

Bookmark

November 7, 1974New England Journal of Medicine

Amputation and Adriamycin in Primary Osteosarcoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does adjuvant adriamycin therapy delay metastases in patients with primary osteosarcoma post-amputation?

Population

21 patients with primary osteosarcoma without detectable metastases, post surgical amputation

Comparison

Adjuvant adriamycin therapy starting median two… vs Historical control

Design

Cohort

Follow-up

median >9 months

Authors

ECEngracio P. CortesMount Sinai Hospital JHJames F. HollandMayo Clinic JWJaw J. WangRoswell Park Comprehensive Cancer Center

Discussion

Member takes

Implication

May support adjuvant adriamycin post-osteosarcoma amputation; leaves open confirmation in randomized trials.

Key Points

To determine whether adjuvant adriamycin chemotherapy reduces recurrence and metastatic spread in patients with primary osteosarcoma without detectable metastases following surgical amputation.
Treated 21 osteosarcoma patients with adjuvant adriamycin (30 mg/m² daily for three consecutive days every four to six weeks for six courses) starting a median of two weeks post-amputation.
Tracked overall survival and pulmonary metastasis-free intervals over a follow-up of one to >32 months and compared outcomes to historical control data (n=145) using life-table analysis.
Nineteen of 21 patients survived after a median follow-up of >9 months, with five total relapses observed (two local and three pulmonary metastases).
Life-table analysis projected that 71% of treated patients remained free of pulmonary metastases at 18 months (95% CI, 43% to 100%), compared to 30% in historical surgical controls.

Structured PICO

Does adjuvant adriamycin therapy delay metastases in patients with primary osteosarcoma post-amputation?

Population

21 patients with primary osteosarcoma without detectable metastases, post surgical amputation

Intervention

Adjuvant adriamycin therapy (30 mg/m2 daily for three days, repeated every four to six weeks for six courses) starting median two weeks after amputation

Comparator

Historical control (series of 145 patients analyzed by Marcove et al.)

Outcome

Freedom from pulmonary metastases at 18 monthshard clinical

Adjuvant adriamycin therapy following amputation for primary osteosarcoma delays the onset of pulmonary metastases compared to historical controls.

Cite This Study

Cortes et al. (1974) studied this question.

synapsesocial.com/papers/6a7377753800ec2ea6a729f7 https://doi.org/10.1056/nejm197411072911903

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark